Should all patients with a remote history of immunotherapy, chemotherapy and/or radiation therapy have a baseline TTE regardless of ASCVD risk?   

The current ASCVD risk assessment calculators we have available do not contain cancer-specific parameters and thus are inadequate for accurate assessment of a cancer survivor's risk of developing CHF and ischemic heart disease. If patients have received mediastinal radiation therapy or high-dose ant...

Cardiac testing should be tailored to the type of cardiotoxic therapy they have received. Some patients may be at increased risk of developing ischemic heart disease, peripheral artery disease, or HTN. Patients who are establishing cardiology care after exposure to cardiotoxic cancer therapy such as...